Synapse - David Scheinberg

Results (30)

Depleting T regulatory cells by targeting intracellular Foxp3 with a TCR mimic antibody

Journal Article

Dao, T.; Mun, S. S.; Scott, A. C.; Jarvis, C. A.; Korontsvit, T.; Yang, Z.; Liu, L.; Klatt, M. G.; Guerreiro, M.; Selvakumar, A.; more...
OncoImmunology (2019)

Fulltext@MSK | Save

Phase 2 trial of a multivalent WT1 peptide vaccine (galinpepimut-S) in acute myeloid leukemia

Journal Article

Maslak, P. G.; Dao, T.; Bernal, Y.; Chanel, S. M.; Zhang, R.; Frattini, M.; Rosenblat, T.; Jurcic, J. G.; Brentjens, R. J.; Arcila, M. E.; more...
Blood Advances (2018)

Fulltext@MSK | Save

Phase II trial of WT1 analog peptide vaccine in adults with acute myeloid leukemia (AML) in first complete remission (CR)

Meeting Abstract

Maslak, P. G.; Dao, T.; Bernal, Y.; Chanel, S. M.; Zhang, R.; Frattini, M. G.; Rosenblat, T. L.; Jurcic, J. G.; Rampal, R.; Park, J. H.; more...
Journal of Clinical Oncology (2016)

Fulltext@MSK | Save

Targeting the intracellular WT1 oncogene product with a therapeutic human antibody

Journal Article

Dao, T.; Yan, S. ; Veomett, N.; Pankov, D.; Zhou, L.; Korontsvit, T.; Scott, A.; Whitten, J.; Maslak, P.; Casey, E.; more...
Science Translational Medicine (2013)

Fulltext@MSK | Save

Phase II trial of WT1 analog peptide vaccine in patients with acute myeloid leukemia (AML) in complete remission (CR)

Meeting Abstract

Rosenblat, T. L.; Frattini, M. G.; Chanel, S. M.; Dao, T.; Bernal, Y.; Jurcic, J. G.; Zhang, R.; Simancek, P.; Tallman, M. S.; Scheinberg, D. A.; more...
Blood (2012)

Fulltext@MSK | Save

Phase I trial of the targeted alpha-particle nano-generator actinium-225 ((225)Ac-lintuzumab) (anti-CD33; HuM195) in acute myeloid leukemia (AML)

Meeting Abstract

Jurcic, J. G.; Rosenblat, T. L.; McDevitt, M. R.; Pandit-Taskar, N.; Carrasquillo, J. A.; Chanel, S. M.; Ryan, C.; Frattini, M. G.; Cicic, D.; Larson, S. M.; more...
Journal of Clinical Oncology (2011)

Fulltext@MSK | Save

Phase I trial of the targeted alpha-particle nano-generator actinium-225 (ac-225)-lintuzumab (anti-CD33; HuM195) in acute myeloid leukemia (AML)

Meeting Abstract

Jurcic, J. G.; Rosenblat, T. L.; McDevitt, M. R.; Pandit-Taskar, N.; Carrasquillo, J. A.; Chanel, S. M.; Zikaras, K.; Frattini, M. G.; Maslak, P. G.; Cicic, D.; more...
Blood (2011)

Fulltext@MSK | Save

Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias

Journal Article

Brentjens, R. J.; Riviere, I.; Park, J. H.; Davila, M. L.; Wang, X.; Stefanski, J.; Taylor, C.; Yeh, R.; Bartido, S.; Borquez-Ojeda, O.; more...
Blood (2011)

Fulltext@MSK | Save

Sequential cytarabine and α-particle immunotherapy with bismuth-213-lintuzumab (HuM195) for acute myeloid leukemia

Journal Article

Rosenblat, T. L.; McDevitt, M. R.; Mulford, D. A.; Pandit-Taskar, N.; Divgi, C. R.; Panageas, K. S.; Heaney, M. L.; Chanel, S.; Morgenstern, A.; Sgouros, G.; more...
Clinical Cancer Research (2010)

Fulltext@MSK | Save

Vaccination with synthetic analog peptides derived from WT1 oncoprotein induces T-cell responses in patients with complete remission from acute myeloid leukemia

Journal Article

Maslak, P. G.; Dao, T.; Krug, L. M.; Chanel, S.; Korontsvit, T.; Zakhaleva, V.; Zhang, R.; Wolchok, J. D.; Yuan, J.; Pinilla-Ibarz, J.; more...
Blood (2010)

Fulltext@MSK | Save